Martin Bauer1, Sandra Barna2, Matthias Blaickner2,3, Konstantin Prosenz4, Karsten Bamminger5, Verena Pichler5, Nicolas Tournier6, Marcus Hacker5, Markus Zeitlinger4, Georgios Karanikas5, Oliver Langer4,2,5. 1. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. martin.m.bauer@meduniwien.ac.at. 2. Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria. 3. Center for Medical Physics Biomedical Engineering, Medical University of Vienna, Vienna, Austria. 4. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. 5. Department of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. 6. Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, France.
Abstract
PURPOSE: To assess in healthy volunteers the whole-body distribution and dosimetry of [11C]metoclopramide, a new positron emission tomography (PET) tracer to measure P-glycoprotein activity at the blood-brain barrier. PROCEDURES: Ten healthy volunteers (five women, five men) were intravenously injected with 387 ± 49 MBq of [11C]metoclopramide after low dose CT scans and were then imaged by whole-body PET scans from head to upper thigh over approximately 70 min. Ten source organs (brain, thyroid gland, right lung, myocardium, liver, gall bladder, left kidney, red bone marrow, muscle and the contents of the urinary bladder) were manually delineated on whole-body images. Absorbed doses were calculated with QDOSE (ABX-CRO) using the integrated IDAC-Dose 2.1 module. RESULTS: The majority of the administered dose of [11C]metoclopramide was taken up into the liver followed by urinary excretion and, to a smaller extent, biliary excretion of radioactivity. The mean effective dose of [11C]metoclopramide was 1.69 ± 0.26 μSv/MBq for female subjects and 1.55 ± 0.07 μSv/MBq for male subjects. The two organs receiving the highest radiation doses were the urinary bladder (10.81 ± 0.23 μGy/MBq and 8.78 ± 0.89 μGy/MBq) and the liver (6.80 ± 0.78 μGy/MBq and 4.91 ± 0.74 μGy/MBq) for female and male subjects, respectively. CONCLUSIONS: [11C]Metoclopramide showed predominantly renal excretion, and is safe and well tolerated in healthy adults. The effective dose of [11C]metoclopramide was comparable to other 11C-labeled PET tracers.
PURPOSE: To assess in healthy volunteers the whole-body distribution and dosimetry of [11C]metoclopramide, a new positron emission tomography (PET) tracer to measure P-glycoprotein activity at the blood-brain barrier. PROCEDURES: Ten healthy volunteers (five women, five men) were intravenously injected with 387 ± 49 MBq of [11C]metoclopramide after low dose CT scans and were then imaged by whole-body PET scans from head to upper thigh over approximately 70 min. Ten source organs (brain, thyroid gland, right lung, myocardium, liver, gall bladder, left kidney, red bone marrow, muscle and the contents of the urinary bladder) were manually delineated on whole-body images. Absorbed doses were calculated with QDOSE (ABX-CRO) using the integrated IDAC-Dose 2.1 module. RESULTS: The majority of the administered dose of [11C]metoclopramide was taken up into the liver followed by urinary excretion and, to a smaller extent, biliary excretion of radioactivity. The mean effective dose of [11C]metoclopramide was 1.69 ± 0.26 μSv/MBq for female subjects and 1.55 ± 0.07 μSv/MBq for male subjects. The two organs receiving the highest radiation doses were the urinary bladder (10.81 ± 0.23 μGy/MBq and 8.78 ± 0.89 μGy/MBq) and the liver (6.80 ± 0.78 μGy/MBq and 4.91 ± 0.74 μGy/MBq) for female and male subjects, respectively. CONCLUSIONS: [11C]Metoclopramide showed predominantly renal excretion, and is safe and well tolerated in healthy adults. The effective dose of [11C]metoclopramide was comparable to other 11C-labeled PET tracers.
Authors: Daniëlle M E van Assema; Mark Lubberink; Martin Bauer; Wiesje M van der Flier; Robert C Schuit; Albert D Windhorst; Emile F I Comans; Nikie J Hoetjes; Nelleke Tolboom; Oliver Langer; Markus Müller; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel Journal: Brain Date: 2011-11-26 Impact factor: 13.501
Authors: William C Kreisl; Jeih-San Liow; Nobuyo Kimura; Nicholas Seneca; Sami S Zoghbi; Cheryl L Morse; Peter Herscovitch; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2010-03-17 Impact factor: 10.057
Authors: Lucy Sasongko; Jeanne M Link; Mark Muzi; David A Mankoff; Xiaodong Yang; Ann C Collier; Steven C Shoner; Jashvant D Unadkat Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875
Authors: Jasper van der Aart; William A Hallett; Eugenii A Rabiner; Jan Passchier; Robert A Comley Journal: Nucl Med Biol Date: 2011-10-26 Impact factor: 2.408
Authors: Viktoria Zoufal; Severin Mairinger; Mirjam Brackhan; Markus Krohn; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Wanek; Nicolas Tournier; Martin Bauer; Jens Pahnke; Oliver Langer Journal: J Nucl Med Date: 2019-12-05 Impact factor: 11.082
Authors: Anand K Deo; Soo Borson; Jeanne M Link; Karen Domino; Janet F Eary; Ban Ke; Todd L Richards; David A Mankoff; Satoshi Minoshima; Finbarr O'Sullivan; Sara Eyal; Peng Hsiao; Ken Maravilla; Jashvant D Unadkat Journal: J Nucl Med Date: 2014-05-19 Impact factor: 11.082